MY207509A - Treatment of asthma with anti-tslp antibody - Google Patents
Treatment of asthma with anti-tslp antibodyInfo
- Publication number
- MY207509A MY207509A MYPI2019005927A MYPI2019005927A MY207509A MY 207509 A MY207509 A MY 207509A MY PI2019005927 A MYPI2019005927 A MY PI2019005927A MY PI2019005927 A MYPI2019005927 A MY PI2019005927A MY 207509 A MY207509 A MY 207509A
- Authority
- MY
- Malaysia
- Prior art keywords
- asthma
- treatment
- tslp antibody
- tslp
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484864P | 2017-04-12 | 2017-04-12 | |
| US201762553575P | 2017-09-01 | 2017-09-01 | |
| US201762553477P | 2017-09-01 | 2017-09-01 | |
| PCT/US2018/027271 WO2018191479A1 (en) | 2017-04-12 | 2018-04-12 | Treatment of asthma with anti-tslp antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207509A true MY207509A (en) | 2025-02-28 |
Family
ID=62092313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019005927A MY207509A (en) | 2017-04-12 | 2018-04-12 | Treatment of asthma with anti-tslp antibody |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10828365B2 (enExample) |
| EP (1) | EP3609917A1 (enExample) |
| JP (4) | JP7330896B2 (enExample) |
| KR (2) | KR102666879B1 (enExample) |
| CN (1) | CN110573525A (enExample) |
| AU (2) | AU2018253118B2 (enExample) |
| BR (1) | BR112019021482A2 (enExample) |
| CA (1) | CA3059364A1 (enExample) |
| CL (1) | CL2019002897A1 (enExample) |
| CO (1) | CO2019011462A2 (enExample) |
| IL (1) | IL269791B (enExample) |
| JO (1) | JOP20190243A1 (enExample) |
| MX (1) | MX2019012158A (enExample) |
| MY (1) | MY207509A (enExample) |
| PE (1) | PE20200484A1 (enExample) |
| PH (1) | PH12019502331A1 (enExample) |
| SG (1) | SG11201909322VA (enExample) |
| TN (1) | TN2019000289A1 (enExample) |
| TW (2) | TW202523688A (enExample) |
| UY (1) | UY37676A (enExample) |
| WO (1) | WO2018191479A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108350070B (zh) * | 2015-09-09 | 2022-01-28 | 诺华股份有限公司 | 胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法 |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| US12404323B2 (en) * | 2019-06-04 | 2025-09-02 | Jiangsu Hengrui Medicine Co., Ltd | Antibody capable of binding to thymic stromal lymphopoietin and use thereof |
| JP7597784B2 (ja) * | 2019-07-11 | 2024-12-10 | タヴォテック バイオセラピューティクス （ホン コン） リミテッド | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤 |
| CN113423733B (zh) * | 2019-09-04 | 2023-09-22 | 正大天晴药业集团股份有限公司 | 结合tslp的抗体及其用途 |
| KR20220088752A (ko) * | 2019-10-28 | 2022-06-28 | 메드임뮨 리미티드 | 흉선 기질 림포포이에틴 (tslp)-결합 항체들의 건조 분말 제형 및 이의 사용 방법 |
| CN112876564B (zh) * | 2019-11-29 | 2022-07-15 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| CA3155759A1 (en) * | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| CA3166964A1 (en) * | 2020-02-13 | 2021-08-19 | Alexis Lueras | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
| WO2021163588A1 (en) * | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| US20230081261A1 (en) * | 2020-02-18 | 2023-03-16 | Amgen Inc. | Formulations of human anti-tslp antibodies and methods of using the same |
| CN113388035A (zh) * | 2020-03-13 | 2021-09-14 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| TW202229339A (zh) * | 2020-12-03 | 2022-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 結合胸腺基質淋巴細胞生成素的抗體及其應用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| US20240309080A1 (en) * | 2021-03-03 | 2024-09-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing anti-tslp antibody |
| AU2022263281A1 (en) * | 2021-04-19 | 2023-11-09 | Medimmune Limited | An anti-tslp fab with improved stability |
| EP4326766A1 (en) | 2021-04-23 | 2024-02-28 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| JP2024516595A (ja) | 2021-04-23 | 2024-04-16 | アムジエン・インコーポレーテツド | 修飾された抗ｔｓｌｐ抗体 |
| CN113683694B (zh) * | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN117106084B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| CN117327176A (zh) * | 2022-06-24 | 2024-01-02 | 南京融捷康生物科技有限公司 | 一种抗tslp的单域抗体及其用途 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202426485A (zh) | 2022-10-26 | 2024-07-01 | 美商安進公司 | 抗ｔｓｌｐ抗體組成物及其用途 |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| TW202523697A (zh) * | 2023-08-25 | 2025-06-16 | 美商普羅特歐拉吉克適美國公司 | 抗ｔｓｌｐ抗體構築體及其用途 |
| CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
| WO2025179220A1 (en) * | 2024-02-22 | 2025-08-28 | Flagship Pioneering Innovations Vi, Llc | Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp) |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| PH12012500843A1 (en) | 2009-11-04 | 2019-07-10 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| TW201201840A (en) * | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| AU2014340129A1 (en) * | 2013-10-23 | 2016-05-26 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| SG11201700901SA (en) * | 2014-08-08 | 2017-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| BR112017019412A2 (pt) | 2015-03-11 | 2018-05-02 | Glaxosmithkline Ip Dev Ltd | proteínas ligadoras de tslp |
| AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
-
2017
- 2017-06-16 JO JOP/2019/0243A patent/JOP20190243A1/ar unknown
-
2018
- 2018-04-12 PE PE2019002026A patent/PE20200484A1/es unknown
- 2018-04-12 EP EP18721605.6A patent/EP3609917A1/en active Pending
- 2018-04-12 KR KR1020197033043A patent/KR102666879B1/ko active Active
- 2018-04-12 CA CA3059364A patent/CA3059364A1/en active Pending
- 2018-04-12 MX MX2019012158A patent/MX2019012158A/es unknown
- 2018-04-12 AU AU2018253118A patent/AU2018253118B2/en active Active
- 2018-04-12 UY UY0001037676A patent/UY37676A/es not_active Application Discontinuation
- 2018-04-12 TN TNP/2019/000289A patent/TN2019000289A1/en unknown
- 2018-04-12 BR BR112019021482-8A patent/BR112019021482A2/pt unknown
- 2018-04-12 KR KR1020247015858A patent/KR20240070727A/ko active Pending
- 2018-04-12 CN CN201880026131.3A patent/CN110573525A/zh active Pending
- 2018-04-12 US US15/951,602 patent/US10828365B2/en active Active
- 2018-04-12 JP JP2019555854A patent/JP7330896B2/ja active Active
- 2018-04-12 WO PCT/US2018/027271 patent/WO2018191479A1/en not_active Ceased
- 2018-04-12 TW TW113133318A patent/TW202523688A/zh unknown
- 2018-04-12 SG SG11201909322V patent/SG11201909322VA/en unknown
- 2018-04-12 IL IL269791A patent/IL269791B/en unknown
- 2018-04-12 TW TW107112622A patent/TWI856945B/zh active
- 2018-04-12 MY MYPI2019005927A patent/MY207509A/en unknown
-
2019
- 2019-10-11 PH PH12019502331A patent/PH12019502331A1/en unknown
- 2019-10-11 CL CL2019002897A patent/CL2019002897A1/es unknown
- 2019-10-16 CO CO2019011462A patent/CO2019011462A2/es unknown
-
2020
- 2020-11-09 US US17/093,387 patent/US20210052726A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080295A patent/JP2023099233A/ja not_active Withdrawn
-
2024
- 2024-08-02 JP JP2024127900A patent/JP2024150751A/ja active Pending
- 2024-10-08 US US18/909,660 patent/US20250032608A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204735A patent/AU2025204735A1/en active Pending
- 2025-09-04 JP JP2025147176A patent/JP2025170430A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502331A1 (en) | Treatment of asthma with anti-tslp antibody | |
| PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
| MY210545A (en) | Chimeric receptors to flt3 and methods of use thereof | |
| PH12018500482A1 (en) | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| BR112017008710A8 (pt) | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva | |
| MY186352A (en) | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| WO2013006474A3 (en) | Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| MX2020010722A (es) | Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. | |
| NZ746609A (en) | Ilt7 binding molecules and methods of using the same | |
| MX2021006463A (es) | Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. | |
| ZA202205936B (en) | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof | |
| PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
| MX2019013160A (es) | Metodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
| MY201744A (en) | Binding polypeptides and methods of making the same | |
| MX2025008918A (es) | Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp | |
| MX2025013757A (es) | Tratamiento para el asma dependiente de corticosteroides con anticuerpo anti-tslp | |
| MX2010007355A (es) | Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion. |